NICE - Endorsed Technology Appraisals 2015/2016

It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.

Technology Appraisals Endorsement Process

The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;

NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13

For information, details of the previous arrangement can be found on the following circular;

NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11

2015/2016

The following technology appraisals have been endorsed during 2015/16. Information on technology appraisals endorsed in previous years can be found on the homepage.

Fully Endorsed

March 2016

NICE TA 385 - Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (review of TA132)
- Note - this guidance updates and replaces TA132, which was endorsed by the DoH in February 2008
NICE TA 384 - Nivolumab for treating advanced (unresectable or metastatic) melanoma

February 2016

NICE TA 381 - Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
- This guidance has been updated and replaced by TA620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer, which was endorsed by the DoH in February 2020.
NICE TA 380 - TA 380 - Panobinostat for treating multiple myeloma in people who have received at least one prior therapy
NICE TA 379 - Nintedanib for treating idiopathic pulmonary fibrosis
NICE TA 378 - Ramucirumab for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma after chemotherapy
NICE TA 377 - Enzalutamide for treating metastatic hormone-relapsed prostate cancer not previously treated with chemotherapy
NICE TA 376 - Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases
- Note - This guidance has been updated and replaced by TA 412 - Radium-223 dichloride for treating metastatic hormone relapsed prostate cancer with bone metastases, which was endorsed by the DoH in October 2016
NICE TA 375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
- Note - Note this guidance has been partially updated and should be read in conjunction with TA715 – Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed’. This updates and replaces TA130 endorsed by DoH in July 2008, TA186 endorsed by the DoH in December 2011 and TA280 endorsed by the DoH in May 2013. It also partially updates TA225 endorsed by DoH in December 2011 and TA247 endorsed by the DoH in March 2012.
NICE TA 383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
- This updates and replaces TA143 endorsed by DoH in February 2009 and TA233 endorsed by the DoH in December 2011.

January 2016

NICE TA 374 - Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175)
- This updates and replaces TA162, which was endorsed by the DoH in March 2009.
NICE TA 373 - Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (including review of TA35)
NICE TA 372 - Apremilast for treating active psoriatic arthritis
- This guidance has been updated and replaced by TA433 - Apremilast for treating active psoriatic arthritis, which was endorsed by the DoH in March 2017.
NICE TA 371 - Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane
- This guidance has been updated and replaced by TA458 - Trastuzumab emtansine for treating HER2 positive advanced breast cancer after trastuzumab and a taxane, which was endorsed by the DoH in August 2017.
NICE TA 370 - Bortezomib for previously untreated mantle cell lymphoma
NICE TA 369 - Ciclosporin for treating dry eye disease which has not improved after treatment with artificial tears

September 2015

August 2015

June 2015

May 2015

NICE TA 338 - Pomalidomide for treating relapsed and refractory multiple myeloma previously treated with both lenalidomide and bortezomib
- This guidance has been updated and replaced by TA427 - Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib, which was endorsed by the DoH in February 2017.
NICE TA 337 - Rifaximin for the maintenance treatment of hepatic encephalopathy
NICE TA 336 - Empagliflozin in combination therapy for treating type 2 diabetes
NICE TA 335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
NICE TA 330 - Sofosbuvir for treating chronic hepatitis C

Endorsed with caveats

None

Not Endorsed as Applicable to Northern Ireland